Shakour Neda, Karami Shima, Iranshahi Mehrdad, Butler Alexandra E, Sahebkar Amirhossein
Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Diabetes Metab Syndr. 2024 Jan;18(1):102934. doi: 10.1016/j.dsx.2023.102934. Epub 2023 Dec 23.
Scar tissue accumulation in organs is the underlying cause of many fibrotic diseases. Due to the extensive array of organs affected, the long-term nature of fibrotic processes and the large number of people who suffer from the negative impact of these diseases, they constitute a serious health problem for modern medicine and a huge economic burden on society. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of anti-diabetic pharmaceuticals that offer additional benefits over and above their glucose-lowering properties; these medications modulate a variety of diseases, including fibrosis. Herein, we have collated and analyzed all available research on SGLT2is and their effects on organ fibrosis, together with providing a proposed explanation as to the underlying mechanisms.
PubMed, ScienceDirect, Google Scholar and Scopus were searched spanning the period from 2012 until April 2023 to find relevant articles describing the antifibrotic effects of SGLT2is.
The majority of reports have shown that SGLT2is are protective against lung, liver, heart and kidney fibrosis as well as arterial stiffness. According to the results of clinical trials and animal studies, many SGLT2 inhibitors are promising candidates for the treatment of fibrosis. Recent studies have demonstrated that SGLT2is affect an array of cellular processes, including hypoxia, inflammation, oxidative stress, the renin-angiotensin system and metabolic activities, all of which have been linked to fibrosis.
Extensive evidence indicates that SGLT2is are promising treatments for fibrosis, demonstrating protective effects in various organs and influencing key cellular processes linked to fibrosis.
器官中的瘢痕组织积累是许多纤维化疾病的根本原因。由于受影响的器官范围广泛、纤维化过程的长期性以及众多人受到这些疾病负面影响，它们对现代医学构成严重的健康问题，并给社会带来巨大的经济负担。钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）是一类相对较新的抗糖尿病药物，除了具有降血糖特性外还具有其他益处；这些药物可调节多种疾病，包括纤维化。在此，我们整理并分析了所有关于SGLT2is及其对器官纤维化影响的现有研究，并对其潜在机制提出了一种解释。
检索了2012年至2023年4月期间的PubMed、ScienceDirect、谷歌学术和Scopus，以查找描述SGLT2is抗纤维化作用的相关文章。
大多数报告表明，SGLT2is对肺、肝、心脏和肾脏纤维化以及动脉僵硬度具有保护作用。根据临床试验和动物研究结果，许多SGLT2抑制剂是治疗纤维化的有前景的候选药物。最近的研究表明，SGLT2is会影响一系列细胞过程，包括缺氧、炎症、氧化应激、肾素-血管紧张素系统和代谢活动，所有这些都与纤维化有关。
大量证据表明，SGLT2is是有前景的纤维化治疗药物，在各种器官中显示出保护作用，并影响与纤维化相关的关键细胞过程。
